This Week in JAMA
Abstract
Aliskiren, Mortality, and Heart Failure Readmissions Among patients with heart failure, rates of early rehospitalization and mortality are high. In a randomized, placebo-controlled trial that enrolled 1639 patients hospitalized for heart failure with reduced left ventricular ejection fraction, Gheorghiade and colleagues investigated whether adding aliskiren—a direct renin inhibitor—to standard therapy would decrease the rate of cardiovascular mortality or rehospitalization for...